EU/3/07/444

Table of contents

About

On 13 April 2007, orphan designation (EU/3/07/444) was granted by the European Commission to Oxford Regulatory Solutions Ltd, United Kingdom, for pralatrexate for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated).

The sponsorship was transferred to European Medical Advisory Services Limited, United Kingdom, in December 2007 and subsequently to Allos Therapeutics Limited, United Kingdom, in April 2010.

Key facts

Active substance
Pralatrexate
Disease / condition
Treatment of peripheral T-cell lymphoma (nodal, othe extranodal and leukaemic/disseminated)
Date of decision
13/04/2007
Outcome
Positive
Orphan decision number
EU/3/07/444

Sponsor's contact details

Allos Therapeutics Limited
71 Knowl Piece
Wilbury Way
Hitchin
Hertfordshire SG4 OTY
United Kingdom
Telephone: +44 1462 424 416
Telefax: +44 1462 600 453

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating